Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Chief Scientific Officer | December 20, 2023 | December 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zentalis Pharmaceuticals, Inc.
Report date December 20, 2023 · Filed December 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 834,931 |
Reported balance
After 2023-12-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-20 · Gift · Disposed 24,158 · Balance 834,931 F1: The Reporting Person transferred 24,158 shares to the Raising Hope Foundation, a charitable foundation of which the Reporting Person is a director. The Reporting Person has voting and investment power over all securities owned by the Raising Hope Foundation. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 15,000 |
Reported balance
Holding disclosure · report date 2023-12-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 15,000 F2: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectAs UTMA custodian for sons | 350 |
Reported balance
Holding disclosure · report date 2023-12-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 350 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person transferred 24,158 shares to the Raising Hope Foundation, a charitable foundation of which the Reporting Person is a director. The Reporting Person has voting and investment power over all securities owned by the Raising Hope Foundation.
F2: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2021 Filed Mar 8, 2021 06:03 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,700 | $45.07 | $166,747.16 |
DisclosureSEC source: 0001725160-21-000055 · wf-form4_161520139330796.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 63,660 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $45.00 to $45.32. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 16:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,210 | $41.65 | $175,351.55 |
DisclosureSEC source: 0001725160-21-000053 · wf-form4_161480742303033.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 67,360 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:02 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 56,250 | $0.00 Strike: $38.76 | $0.00 |
DisclosureSEC source: 0001725160-21-000039 · wf-form4_161352014224856.xml · derivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 56,250 shares Expires 2031-02-10 F3 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:02 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000039 · wf-form4_161352014224856.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044,464 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 17:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,769 | $37.82 | $66,900.75 |
DisclosureSEC source: 0001725160-21-000020 · wf-form4_161239286936240.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 71,570 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $37.59 to $38.55. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 17:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,441 | $37.29 | $91,017.57 |
DisclosureSEC source: 0001725160-21-000020 · wf-form4_161239286936240.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 73,339 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $36.59 to $37.55. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 20:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 700 | $53.24 | $37,265.97 |
DisclosureSEC source: 0001725160-21-000006 · wf-form4_160998268839119.xml · nonDerivative · entry 9 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 75,780 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F10 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.17 to $53.44. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 20:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,232 | $52.66 | $222,857.54 |
DisclosureSEC source: 0001725160-21-000006 · wf-form4_160998268839119.xml · nonDerivative · entry 8 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 76,480 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F9 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.12 to $53.11. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 20:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,507 | $51.49 | $77,590.16 |
DisclosureSEC source: 0001725160-21-000006 · wf-form4_160998268839119.xml · nonDerivative · entry 7 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 80,712 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.06 to $51.97. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 20:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,981 | $50.40 | $99,845.17 |
DisclosureSEC source: 0001725160-21-000006 · wf-form4_160998268839119.xml · nonDerivative · entry 6 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 82,219 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.82 to $50.80. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 20:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 7,625 | $53.10 | $404,849.38 |
DisclosureSEC source: 0001725160-21-000006 · wf-form4_160998268839119.xml · nonDerivative · entry 5 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025,713 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.82 to $53.47. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 20:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 9,701 | $52.42 | $508,529.33 |
DisclosureSEC source: 0001725160-21-000006 · wf-form4_160998268839119.xml · nonDerivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,338 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.82 to $52.79. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 20:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,842 | $51.33 | $248,533.57 |
DisclosureSEC source: 0001725160-21-000006 · wf-form4_160998268839119.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043,039 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.82 to $51.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 20:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,399 | $50.39 | $221,645.37 |
DisclosureSEC source: 0001725160-21-000006 · wf-form4_160998268839119.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,047,881 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.82 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 24, 2020 Filed Jan 6, 2021 20:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000006 · wf-form4_160998268839119.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,052,280 Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 20:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 659 | $54.39 | $35,840.57 |
DisclosureSEC source: 0001725160-20-000058 · wf-form4_160747785819891.xml · nonDerivative · entry 6 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,053,880 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $54.15 to $54.89. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 20:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 8,395 | $53.71 | $450,904.68 |
DisclosureSEC source: 0001725160-20-000058 · wf-form4_160747785819891.xml · nonDerivative · entry 5 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,054,539 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.15 to $54.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 20:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,637 | $52.53 | $85,990.46 |
DisclosureSEC source: 0001725160-20-000058 · wf-form4_160747785819891.xml · nonDerivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062,934 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.15 to $53.13. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 20:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 201 | $50.84 | $10,218.64 |
DisclosureSEC source: 0001725160-20-000058 · wf-form4_160747785819891.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,064,571 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.53 to $51.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 20:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 6,533 | $51.17 | $334,311.90 |
DisclosureSEC source: 0001725160-20-000058 · wf-form4_160747785819891.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,064,772 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.02 to $52.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 20:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,632 | $50.76 | $285,895.53 |
DisclosureSEC source: 0001725160-20-000058 · wf-form4_160747785819891.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,071,305 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.02 to $51.01. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 17:57 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,372 | $54.53 | $74,811.73 |
DisclosureSEC source: 0001725160-20-000051 · wf-form4_160703621641102.xml · nonDerivative · entry 5 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 84,200 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $54.26 to $54.86. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 17:57 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,943 | $53.69 | $158,010.26 |
DisclosureSEC source: 0001725160-20-000051 · wf-form4_160703621641102.xml · nonDerivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 85,572 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.245 to $54.24. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 17:57 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,500 | $52.58 | $78,863.40 |
DisclosureSEC source: 0001725160-20-000051 · wf-form4_160703621641102.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 88,515 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.16 to $53.15. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 17:57 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,505 | $51.59 | $129,229.94 |
DisclosureSEC source: 0001725160-20-000051 · wf-form4_160703621641102.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 90,015 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.13 to $52.06. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 17:57 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 100 | $49.68 | $4,968.00 |
DisclosureSEC source: 0001725160-20-000051 · wf-form4_160703621641102.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 92,520 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 20:34 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 400 | $47.55 | $19,018.08 |
DisclosureSEC source: 0001725160-20-000041 · wf-form4_160635447424149.xml · nonDerivative · entry 6 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 92,620 F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $47.51 to $47.695. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 20:34 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,064 | $46.71 | $189,849.35 |
DisclosureSEC source: 0001725160-20-000041 · wf-form4_160635447424149.xml · nonDerivative · entry 5 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 93,020 F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $46.47 to $47.20. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 20:34 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,961 | $46.28 | $183,311.52 |
DisclosureSEC source: 0001725160-20-000041 · wf-form4_160635447424149.xml · nonDerivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 97,084 F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $45.47 to $46.46. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 20:34 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 101,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-20-000041 · wf-form4_160635447424149.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 101,045 F2 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 20:34 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 101,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-20-000041 · wf-form4_160635447424149.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,076,937 Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 16:30 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 99,246 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010601 · doc4.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,650 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest over a fifteen month period following the grant date. Read SEC document |
| April 07, 2020 Filed Nov 25, 2020 20:34 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | PurchaseCommon Stock | 350 | $18.00 | $6,300.00 |
DisclosureSEC source: 0001725160-20-000041 · wf-form4_160635447424149.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,177,982 F1 · balance_after: Includes 632,982 shares of common stock received on October 28, 2020 in a pro-rata distribution in-kind that was exempt from reporting under Rule 16a-9. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.